| Title |
Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, May 2013
|
| DOI | 10.1007/s00280-013-2179-9 |
| Pubmed ID | |
| Authors |
Christopher M. Stephenson, Robert D. Levin, Thomas Spector, Christopher G. Lis |
| Abstract |
This phase I clinical trial evaluated the safety, tolerability, and pharmacokinetics of high-dose intravenous (i.v.) ascorbic acid as a monotherapy in patients with advanced solid tumors refractory to standard therapy. |
X Demographics
The data shown below were collected from the profiles of 22 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 4 | 18% |
| United States | 2 | 9% |
| Netherlands | 2 | 9% |
| Saint Barthélemy | 1 | 5% |
| Germany | 1 | 5% |
| Unknown | 12 | 55% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 21 | 95% |
| Practitioners (doctors, other healthcare professionals) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 213 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 1% |
| Portugal | 1 | <1% |
| Colombia | 1 | <1% |
| Belgium | 1 | <1% |
| Canada | 1 | <1% |
| Denmark | 1 | <1% |
| Lebanon | 1 | <1% |
| Unknown | 204 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 31 | 15% |
| Researcher | 28 | 13% |
| Student > Master | 27 | 13% |
| Student > Ph. D. Student | 26 | 12% |
| Other | 18 | 8% |
| Other | 37 | 17% |
| Unknown | 46 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 68 | 32% |
| Agricultural and Biological Sciences | 22 | 10% |
| Biochemistry, Genetics and Molecular Biology | 21 | 10% |
| Nursing and Health Professions | 18 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 3% |
| Other | 26 | 12% |
| Unknown | 51 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 56. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2023.
All research outputs
#770,026
of 25,758,695 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#14
of 2,576 outputs
Outputs of similar age
#5,468
of 206,900 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#1
of 26 outputs
Altmetric has tracked 25,758,695 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,576 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,900 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.